The Effects of Externally Administered Insulin-like Growth Factor-I on Glomerulosclerosis during Compensatory Renal Hypertrophy in Rats.
- Author:
Chang Jun YOON
1
;
Chul Kyu CHO
;
Tong Choon PARK
Author Information
1. Department of Urology, College of Medicine, Yeungnam University, Daegu, Korea.
- Publication Type:Original Article
- Keywords:
IGF-I;
Glomerulosclerosis;
Rat kidney
- MeSH:
Animals;
Body Weight;
Growth Hormone;
Humans;
Hypertrophy*;
Insulin-Like Growth Factor I;
Kidney;
Kidney Failure, Chronic;
Nephrectomy;
Parturition;
Rats*;
Rats, Sprague-Dawley
- From:Korean Journal of Urology
2001;42(4):406-412
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Among renotropic agents, a growth hormone (GH) independent insulin-like growth factor-I (IGF-I) improves renal function without inducing glomerulosclerosis and its potential for treating renaldisease is increasing. With this in mind, this study was designed to find out the effects of externallyadministered IGF-I toward preventing glomerulosclerosis after renal volume loss in rats. MATERIALS AND METHODS: Sprague-Dawley rats (110-130gm) were divided into four groups in accordance with 3/4 nephrectomyand/or IGF-I administration. The 3/4 nephrectomy was performed at 30 days after birth, and recombinanthuman IGF-I was administered for 60 days after 3/4 nephrectomy. The change of body weight and wet weight of the remnant kidney were determined. The glomerular planar area and percentage of glomerulosclerosiswere measured. RESULTS: The body weight andthe wet weight of remnant kidney were significantly increased after administration of IGF-I in the3/4 nephrectomy group. The glomerular planar area was significantly increased after administration of IGF-I in the 3/4 nephrectomy group, and significant increase in glomerular planar area was observed in the 3/4 nephrectomy group regardless of IGF-I administration. And the percentage of glomerulosclerosis was significantly decreased. CONCLUSIONS: Thus it is concluded that this study proved that the externally administered IGF-I prevents lomerulosclerosis after severe renal volume loss in rats. It may have a potential to become a useful medical agent for suppressing glomerular sclerotic change and facilitating renal function in chronic renal failure patients.
